Lejeune et al. BMC Genomics 2012, 13:91
http://www.biomedcentral.com/1471-2164/13/91




 RESEARCH ARTICLE                                                                                                                              Open Access

Large-scale functional RNAi screen C. elegans
identifies genes regulate dysfunction mutant polyglutamine neurons
François-Xavier Lejeune1†, Lilia Mesrob1†, Frédéric Parmentier1†, Cedric Bicep1,2, Rafael P Vazquez-Manrique1,2,
J Alex Parker1,2,3, Jean-Philippe Vert4,5,6, Cendrine Tourette1,2,7 Christian Neri1,2*


  Abstract
  Background: central goal Huntington’s disease (HD) research identify prioritize candidate targets   neuroprotective intervention, requires genome-scale information modifiers early-stage neuron
  injury HD.
  Results:  performed large-scale RNA interference screen C. elegans strains express N-terminal
  huntingtin (htt) touch receptor neurons. neurons control response light touch. function   strongly impaired expanded polyglutamines (128Q) shown nearly complete loss touch response   adult animals, providing vivo model manipulate early phases expanded-polyQ
  neurotoxicity. total, 6034 genes examined, revealing 662 gene inactivations reduce aggravate
  defective touch response 128Q animals. genes previously implicated HD neurodegenerative
  disease, suggesting screen effectively identified candidate targets HD. Network-based analysis
  emphasized subset high-confidence modifier genes pathways HD including metabolic,
  neurodevelopmental pro-survival pathways. Finally, 49 modifiers 128Q-neuron dysfunction   dysregulated striatum R/2 CHL2 HD mice,  identified.
  Conclusions: Collectively, results highlight relevance HD pathogenesis, providing novel information
  potential therapeutic targets neuroprotection HD.


Background                                                                           biological processes essential cellular
Huntington’s disease (HD) dominantly-inherited dis-                             homeostasis neuron survival. Consistent order caused expanded polyglutamine (polyQ) tracts                                possibility, transcriptomic analyses revealed N-terminal portion huntingtin (htt) char-                              mutant/polyQ-expanded htt expression change acterized striatal cortical degeneration [1].                           expression large number genes caudate
HD pathogenesis involve gain toxic proper-                                nucleus HD subjects [9] brain fragment,
ties mutant htt loss normal htt func-                             knock length mouse models HD [10].
tion, studies emphasized critical role                             Given complexity alterations cells tissues
misfolded N-terminal fragments mutant htt [2,3]                              expressing expanded polyQ/htt, gene perturbation natural products htt processing [4]. Huntingtin                            screens expected shed light mechanisms
thought large number partner proteins                                   critical cell response mutant polyQ
involved variety biological processes [5-8], sug-                            expression. Additionally, integration gene pertur-
gesting polyglutamine expansion htt alter                                bation data types ‘omics data                                                                                      example gene expression profiles HD mice [10] * Correspondence: christian.neri@inserm.fr                                           fulfill need target profiling prioritisation † Contributed equally                                                                HD. particularly important compar-
1
 INSERM, Unit 894, Laboratory Neuronal Cell Biology Pathology,                ing target gene activity regulation neuronal
75014 Paris, France list author information available end article               dysfunction versus neuronal death. 
                                       © 2012 Lejeune et al; licensee BioMed Central  Open Access article distributed terms Creative Commons
                                       Attribution License (http://creativecommons.org/licenses 2.0), permits unrestricted use, distribution, reproduction                                        medium, provided original work properly cited.
 Lejeune et al. BMC Genomics 2012, 13:91                                                                       Page 2 14
http://www.biomedcentral.com/1471-2164/13/91




occurrence neuronal cell loss, neuron dysfunction       Methods thought early-stage component          C. elegans strains
pathogenic process HD [3,11].  neuronal cell       Nematode strains handled using standard methods
dysfunction easily tractable vivo. Interestingly,   [16]. Integrated polyQ strains used study genetic regulation response light touch          previously described [17,18]. Briefly, ID245 (igIs245[mec-
mechanosensory neurons C. elegans             3p::htt57-19Q::CFP; lin-15(+); mec-7p::YFP]) ID1
subject detailed analysis [12]. targeting polyQ         (igIs1[mec-3p::htt57-128Q::CFP; lin-15(+); mec-7p::YFP])
expression C. elegans touch cells, previously gen-      stably express 57 amino acids human
erated model recapitulates early phase           huntingtin (htt) fused CFP control expanded polyQ neurotoxicity, neuronal dys-            promoter mec-3 gene YFP control
function absence cell death [13,14].       promoter mec-7 gene. previously
animals, exon 1 like htt fused CFP expressed        reported ID245 animals moderate loss touch receptor neurons control promo-        response light touch tail ID1 animals
ter mec-3 gene (mec-3p) [14]. promoter        strong loss response light touch tail,
active early stages embryonic development         phenotype accompanied axonal swelling adulthood [15]. Young adults expressing normal        [14]. enhanced RNAi strain YY13 carries polyQs (19Q) moderate loss touch response           rrf-3(mg373) mutation [19] provided Caenor- little change touch cell morphology,            habditis Genetics Center, funded NIH young adults expressing expanded polyQs               National Center Research Resources (NCRR). (128Q) dramatic loss touch response, beha-        construct polyQ strains enhanced RNAi sensitivity
vioral phenotype accompanied strong level        neurons, crossed YY13 animals ID245 axonal dystrophy [14]. Axonal dystrophy followed        ID1 animals generate strain ID448 (igIs245[mec- late-onset axonal degeneration observed older        3p::htt57-19Q::CFP;lin-15(+);mec-7p::YFP];rrf-3(pk1426))
adult animals (unpublished data). loss touch           strain ID447 (igIs1[mec-3p::htt57-128Q::CFP;lin-15
response expanded-polyQ nematodes manipu-           (+);mec-7p::YFP];rrf-3(pk1426)), respectively. ID448
lated genetic means, exemplified protective      ID447 strains tested sensitivity touch
effect sirtuin overexpression aggravating effect    receptor neurons RNAi subsequently used loss function sir-2.1/SIRT1–daf-16/FOXO cell        screen C. elegans ORF-RNAi library (Open Biosys-
survival pathway [14]. animals provide       tems, AL) includes clones C. elegans
vivo model screen modifiers neuron         ORFeome library v1.1 [20] detailed 
dysfunction induced expanded polyQs.  used
128Q nematodes large-scale functional RNA inter-         RNAi screen
ference (RNAi) screen modulation response           Bacterial clones C. elegans ORF-RNAi library
touch. Additionally, used 19Q nematodes test          grown 500 μl LB culture medium supplemen-
subset 128Q-confirmed hits modulation           ted ampicillin (100 μg/ml) tetracyclin (12.5 μg/
response touch 19Q nematodes. end,           ml), induced adding 10 μl IPTG
generated polyQ strains enhanced response             (12.5 mg/ml) 4 hours prior incubation nema-
touch receptor neurons double-standed RNA deliv-           todes. Synchronized L1 larvae obtained hypo-
ered feeding. undertook semi-directed            chlorite extraction using standard methods [16] screening approach test total 6034 genes includ-      grown 20°C Petri dishes ing 5128 genes tested random 906 genes            reach young adult stage. day incubation belong major signaling pathways (16-19). led       96 plates (D0), young adult animals incu- identify 662 genes reduce aggravate     bated  wells contained 33.6 μl loss response light touch knocked          bacterial culture 16.6 μl M9 media supplemented
RNAi 128Q nematodes. Screening 19Q nematodes            cholesterol, ampicillin, tetracyclin, fungizone suggested greater 90  genes specifi-       IPTG. Incubation performed 20°C 4 days
cally modify 128Q cytotoxicity. depth data analysis        animals reached adulthood produce late
emphasized role cell differentiation/survival, meta-    L4 larvae. ensure appropriate feeding nema-
bolic neurodegenerative disease pathways           todes  16.6 μl bacterial cultures expressing
modulation expanded-polyQ cytotoxicity. Addition-          RNAi clones added day 1. day 4, animals
ally, data analysis comparisons gene expression        transferred agar plates allowed recover
data HD mice emphasized potential value           15 minutes. RNAi clones producing lethality, larval RNAi dataset target discovery HD.                 arrest, egg-laying defect, developmental delay  Lejeune et al. BMC Genomics 2012, 13:91                                                                     Page 3 14
http://www.biomedcentral.com/1471-2164/13/91



 abnormalities morphological abnormalities     methods. nematode experiments 
(2243 RNAi clones) excluded analysis.     formed times. Student’s t-tests used RNAi clones did alter nematode growth          statistical analysis YFP mRNA levels YFP morphology, P0 animals (old dark            expression levels.
nematodes) initially incubated manually
removed plate young adults (F1 progeny)        Data analysis assayed light touch response previously         final screening results initially classified using
described [13]. Briefly, touch tests involved scoring   Gene Ontology   annotations Biological Process, response light touch tail using fine     Molecular Function Cellular Component http://
hair. Touch test performed scoring 5 touches     www.geneontology.org/[21]. enrichment tests tail animal 70-90 animals/RNAi clone/test.   performed using Ontologizer v 2.0 [22]. Additionally, Ordinarily, wild-type animals respond backing       used hypergeometric tests test gene set enrich-
away touch. responses recorded        ment [23,24]. gene sets used enrichment analy- animal  example, 4 responses     sis established using core components  
5 tail given 80  responsiveness,       canonical pathways based Wormbook http://www.
mean values responsiveness retained    wormbook.org, KEGG http://www.genome.ad.jp/kegg/
analysis data. score change touch           [25] Panther http://www.pantherdb.org/pathway/.
response (S) calculated [(Percent response -           analyze biological content RNAi
mean baseline)/mean baseline]. Using formula,      clones confirmed modulate 128Q toxicity, 
maximally-achievable score 4.55 (maximal suppression     formed network-boosted data analysis. end, 128Q cytotoxicity, e. 100  responsiveness)     subjected RNAi data spectral decomposition ana-
minimally-achievable score -1 (maximal aggravation       lysis using integrated C. elegans network Wormnet 128Q cytotoxicity). baseline assay        v.2 [26]. large-coverage network contains gene
monitored entire time screening      interaction data established according  incubation animals treated        eral types evidences derived multiple organisms,
vector L4440 96 plates assayed.      including types gene interactions based cumulated baseline entire time screening    gene expression (microarray measurements observed stable (20.6 ± 3 ) cumu-         expression C. elegans mRNAs), protein-protein inter-
lated baseline/month used calculate S scores. Sta-   actions including genome-wide yeast hybrid interac-
tistical analysis performed using way ANOVA         tions C. elegans proteins protein-protein Tukey’s Multiple Comparison Test. decrease       interactions Worm Interactome database [27], risk false positives, RNAi clones scored    genetic interactions WormBase [28], human positive hits (suppressors enhancers) S ± SD      fly ‘interologs’ e. human fly protein interactions
value outside baseline ± (SD*2.6). Initial hits     [29,30], Yeast ‘associalogs’ e. functional interactions
(suppressors, enhancers) tested confirmation    transferred yeast functional gene network [31],
invalidation effect touch response result-    phylogenic profiles (comparative genomics linkages
ing data retained biological content analysis.     derived analysis bacterial archaeal gen- screening assays performed investiga-    omes), gene neighbors citation (literature-mined
tors trained score touch response 128Q      C. elegans gene associations). increase power animals similar way using blind assays.                spectral decomposition analysis detecting pathways,
   Prior performing RNAi screen, efficiency   used homogenous network containing
gene inactivation touch receptor neurons tested      high confidence interactions, Core Wormnet incubating ID447 L1 larvae 96 plates (1 lar-     [26] omitted expression citation
vae  bacteria expressing RNAi      links. perform spectral decomposition analysis, GFP (plasmid pL4417) vector (plasmid               developed enhanced version previously
pL4440). Incubation performed described        described [32] Fourier-like analysis. approach F1 young adults produced. end incu-     based spectral decomposition gene activity
bation, 70-90 animals/genotype moved agar           profiles respect connectivity reference
plates mounted slides, YFP levels touch       network. S scores RNAi screen considered cells (mec-7p target cells) measured high (63X)     ‘signal’ Fourier transformation decomposes
magnification using fluorescence microscope (Zeiss        signal superposition signals different fre-
Axioplan Imaging II) image analysis software            quencies, 40 successive attenuations performed
(Image J). Additionally, YFP mRNA levels mea-          [32]. aim transformations sured qRT-PCR animals using standard          low-frequency signals discard high frequency
 Lejeune et al. BMC Genomics 2012, 13:91                                                                       Page 4 14
http://www.biomedcentral.com/1471-2164/13/91




signals, considered noise, context gene      YFP expression levels mec7-p target cells illustrated
nectivity. logic procedure highly     Figure 1A/B. level YFP mRNA expression inter-connected genes implicated           strongly reduced  80 ) RNAi GFP
pathway fluctuate direction [32].         compared vector (Figure 1C). Additionally, Starting raw RNAi screen data, iteratively        level YFP expression mechanosensory neurons
removed high-frequency components 2.5  time,         control response touch tail (PLM neu-
resulting 40 increasingly smoothed versions         rons) reduced RNAi GFP compared data. Given smoothed gene activity data, consid-         vector (Figure 1D). Collectively, results
ered modules groups connected genes signal       indicated touch receptor neurons F1 young
> mean S-score + SD < mean S-score-SD. Addition-           adults sensitive RNAi. Consistent previous
ally, generate relevant signal        reports [37], little reduction YFP levels robust information, selected modules         detected F0 young adults (data shown).
present 4 th attenuation showed stable gene content (≥ 40  genes value          large-scale functional RNAi screen identifies 662 genes threshold) 2 successive attenuations.   modulate neuron dysfunction expanded- resulting modules filtered redundant gene        polyglutamine nematodes
content functional content remaining mod-          Using 128Q nematodes rrf-3 sensitized 
ules analyzed using Ontologizer v 2.0 [22]. Additionally,     ground, conducted primary RNAi screen used hypergeometric tests annotate signaling        modulation neuronal dysfunction. screen
pathways (gene lists extracted Wormbook, KEGG            based manual quantification response Panther), druggable genes [33], htt partners [7,34]       light touch tail F1 young adult animals. genes involved autophagy, mitochondrial function       screened 6260 RNAi clones equaling 6034 genes synaptic activity (gene lists kindly provided      C. elegans genome (Figure 2). decrease risk CHDI Foundation). Information conservation              false positive, applied stringent threshold humans derived Inparanoid clusters [35].          modification touch response considered sig-
addition tables included  results net-       nificant score touch response outside work-boosted data analysis displayed freely-         mean baseline ± SD*2.6 (Additional file 1: Figure S1).
accessible database  http://www.broca.inserm.fr/          screen identified 2243 RNAi clones (2211 genes)
EHDN2/RNAiscreen) vizualisation modules.           caused toxicity phenotypes lethality, larval database allows users browse results          arrest, egg-laying defect, developmental delay using KEGG/Panther annotations annota-           abnormalities morphological abnormalities, 3101
tions  uses VisANT 3.5 graph           RNAi clones (3054 genes) showed effect visualization [36]. used confidence graphs dis-        916 RNAi clones (769 genes) modulated neuronal
play modules normalizing statistical weights        dysfunction (Figure 2, Additional file 2: Table S1; Addi- functional interactions available Wormnet v 2.0     tional file 3: Table S2). class RNAi clones
[26].                                                         subjected second screen 128Q nematodes,
                                                              led identification 664 RNAi clones 
Results                                                       firmed modulate neuronal dysfunction. clones touch receptor neurons F1 128Q;rrf-3 animals       corresponded 662 genes, consisting 399 genes sensitive RNAi                                             reduced neuronal dysfunction knocked construct polyQ strains enhanced RNAi sensi-          RNAi 263 genes enhanced neuronal dysfunc-
tivity neurons, crossed enhanced RNAi strain        tion knocked RNAi (Additional file 4:
YY13 carries rrf-3(mg373)II mutation [19]           Table S3). previously reported, 128Q nematodes integrated strains express N-terminal            80  decreased touch response tail
(amino acids 1-57) htt control mec3-p        strong level axonal dystrophy, 19Q
YFP control mec7-p [14]. resulted        nematodes 45-50  reduction touch response
strain ID448 (19Q;rrf-3) strain ID447(128Q;rrf-3).        tail significant axonal dystrophy [14]. efficiency gene inactivation touch receptor         screen based manual quantifica-
neurons tested incubating strain ID447 L1 larvae       tion touch response 70-90 animals/RNAi clone, 96 plates bacteria expressing RNAi        considerably labour-intensive time- GFP (plasmid L4417) vector (plasmid          consuming compared faster RNAi screens L4440) F1 young adults produced. Treatment          looking modifiers mutant htt aggregation RNAi GFP induced overall reduction         [38,39], evaluated modifiers 128Q-
 Lejeune et al. BMC Genomics 2012, 13:91                                                                                               Page 5 14
http://www.biomedcentral.com/1471-2164/13/91




 Figure 1 Reduction YFP expression 128Q;rff-3 nematodes treated RNAi GFP. Following incubation ID447 L1 larvae
 bacteria expressing vector (pL4440) RNAi GFP (pL4417) F1 young adults produced, YFP levels PLM
 touch receptor cells measured image analysis, YFP mRNA levels measured qRT-PCR animals.   Representative
 image showing YFP expression (pseudocolored green) animals treated vector. mec-7p target cells indicated.
 insert shows closer view left (PLMl) right (PLMr) PLM cell. (B) Representative image showing reduced YFP expression animals
 treated RNAi GFP. yellow arrow indicates natural auto-fluorescence gut granules. fluorescence present  control animals works internal control light intensity, showing pictures collected confocal microscope  conditions. insert shows closer view PLM cell left (PLMl) right (PLMr). (C) YFP mRNA levels reduced treatment  pL4417. Data means ± SE (n = 5). ***P < 0.001 compared pL4440. (D) YFP expression levels PLM cells reduced treatment  pL4417. Data means ± SEM (n = 3) compiled greater 70 animals/experiment. ***P < 0.001 compared pL4440. Scale bar 100
 μm panels.


neuron dysfunction modify neuronal dys-                         depth data analysis emphasizes modifiers 128Q-
function 19Q;rrf-3 nematodes testing subset                     neuron dysfunction pathways associated 662 genes (245 genes choosen random). 15/                      metabolism, development, survival 245 genes (6.1 ) modulate neuronal dys-                      neurodegenerative disease
function 19Q;rrf-3 nematodes knocked                          662 genes associated modification RNAi (Additional file 5: Table S4), suggesting                     128Q-neuron dysfunction appeared encompass vari- 662 genes emphasized screens 128Q;                       ety biological processes (cell death, protein folding,
rrf-3 nematodes specifically modify 128Q cytotoxicity.                     intracellular transport, metabolic processes, response Genome-wide RNAi screens previously aimed identi-                       stress, stress-activated pathways) role fying modifiers polyQ aggregation C. elegans                         neurodegenerative disease pathogenesis suggested [40,41], Consistent notion aggregation                   functional classification using annotations (Fig-
cytotoxicity genetically uncoupled [41],                   ure 3, Additional file 7: Tables S6; Additional file 8:
lap RNAi screen small 12 modifiers                       Table S7). assess biological content cor- 128Q-neuron dysfunction previously                             responding modifiers 128Q-neuron dysfunction,
enhance aggregation 35Q-peptides                               performed types analysis.  used gene
knocked RNAi [40] modifiers                        lists describing major signaling pathways  Materials 128Q-neuron dysfunction previously sup-                        Methods) perform gene set enrichment analyses.
press aggregation 35Q-peptides knocked-                        analysis performed genes aggra- RNAi [41] (Additional file 6: Table S5).                           vate  referred ‘protection-associated’ PA
 Lejeune et al. BMC Genomics 2012, 13:91                                                                         Page 6 14
http://www.biomedcentral.com/1471-2164/13/91




 Figure 2 Overview screening data analysis strategy.


genes) suppress  referred ‘pathogenic             Toll receptor signaling [44]. observations
process-associated’ PPA genes) 128Q-neuron dys-                illustrated revelance RNAi dataset neuro-
function knocked RNAi. Pathway analy-                degeneration. Given PPA genes constitute
sis PA genes identified metabolic pathways              preferred targets therapeutic intervention, example involved glycolysis              results suggested targets early-
amino acid metabolism (Table 1). Consistent              stage neuroprotection HD lie pathways
notion mutant htt expression dysregulate               important neuronal cell differentiation large number genes alter variety biological           survival.
processes [3,10], pathway analysis PPA genes identi-          contrast metabolic pathways fied main pathway categories, including pathways            simple structure, pathways respond exter-
primarily involved metabolism (glycolysis, amino acid          nal stimuli regulate gene expression highly
metabolism), cytokine signaling/immune (inter-             inter-connected, highly-branched
feron-gamma signaling, interleukin signaling, Toll recep-         structures biological outcomes. Additionally,
tor signaling) cellular differentiation                   RNAi-based screens generate noise tar-
homeostasis (IGF pathway, angiogenesis, integrin signal-          effects variations degree knockdown ing, p53 pathway glucose deprivation, FGF signaling,           target genes.  map RNAi activity func-
EGF signaling, Toll receptor signaling) (Table 2). Inter-         tional clusters identify reliable set estingly, category included Alzheimer’s dis-       genes RNAi hits, used network-based
ease (AD)-amyloid secretase pathway, pathways                     approach. end, used Fourier-like analysis
previously associated neuroprotection HD            [32] based reference network Wormnet [26]. IGF signaling [14] FGF signaling [42], pathways          enhance discriminative power reliability play role neurodegenerative disease pathogen-          analysis, developed applied optimized version
esis EGF signaling [43], pathways having            Fourier-like analysis  Materials Methods).
dual role neurodegeneration neuroprotection                analyzed gene set score activity
 Lejeune et al. BMC Genomics 2012, 13:91                                                                                                  Page 7 14
http://www.biomedcentral.com/1471-2164/13/91




 Figure 3 Gene Ontology classification genes modulate neuronal dysfunction induced expanded polyQ expression. Genes
 classified based functional annotations categories ‘Biological Process’, ‘Molecular Function’ ‘Cellular component’. Pie-
 charts frequent ‘Biological process’ categories (corresponding 18 genes) shown gene inactivations reduced
 128Q-neuron dysfunction   aggravated neuronal dysfunction (B). number genes indicated. indicated
 supplementary tables (Supplementary Tables 4-5) complete lists genes category.
 Lejeune et al. BMC Genomics 2012, 13:91                                                                                                    Page 8 14
http://www.biomedcentral.com/1471-2164/13/91




Table 1 Pathway analysis 263 genes enhanced 128Q-neuron dysfunction knocked RNAi
Pathway                              P value Gene
Ascorbate aldarate               0.00000 B0218.8/clec-52, C01G6.1/aqp-2, C08B11.8, C12C8.2, C13B9.1, C36E8.3/pxd-1, C50D2.8, C52B9.1/cka-2,
metabolism                                   C52E4.1/cpr-1, C53B7.3, C54C8.9/nlp-39, D1025.4/nspc-20, D1086.3, F08B1.1/vhp-1, F29G6.2, F38E11.1/hsp-
                                             12.3, F45C12.7/btb-6, F46H5.3, F49E12.1, F54B11.3/unc-84, F54F7.3, F56D6.2/clec-67, K07E3.3/dao-3,
                                             K08D8.3, K09C4.5, M02F4.7/clec-265, M03F4.7/calu-1, T07H3.3/math-38, T16H12.1, T23B3.2, T23H2.2/snt-4,
                                             W08D2.4/fat-3, Y38H6C.3/dct-14, ZC410.5, ZC416.6, ZK6.11
Starch sucrose metabolism        0.00119 F57B10.7/tre-1, R05F9.6, T22F3.3, Y87G2A.8/gpi-1
Tyrosine metabolism                  0.00535 B0334.11/ooc-3, F46C3.1/pek-1, M110.5/dab-1
Amino sugar nucleotide           0.01885 F22B3.4, R05F9.6, Y87G2A.8/gpi-1
sugar metabolism
Glycolysis                           0.03209 T03F1.3/pgk-1, Y87G2A.8/gpi-1
Glycolysis/Gluconeogenesis           0.03332 R05F9.6, T03F1.3/pgk-1, Y87G2A.8/gpi-1
Fatty acid biosynthesis              0.03415 W09B6.1/pod-2
Pentose phosphate pathway            0.04375 R05F9.6, Y87G2A.8/gpi-1
Pathway analysis based hypergeomeric tests using pathways Wormbook, KEGG Panther. P < 0.05 considered significant results shown increasing P values.


Table 2 Pathway analysis 399 genes reduced 128Q-neuron dysfunction knocked RNAi
Pathway                                 P value Gene
Ascorbate aldarate metabolism       0.00000 B0281.5, B0286.3, B0478.1/jnk-1, C06B3.4/stdh-1, C08E3.4/fbxa-161, C08F8.5/fbxb-9, C09G1.1/pqn-11,
                                                C10C5.4, C10C5.5, C10G11.5/pnk-1, C17G10.5/lys-8, C17H12.8, C39D10.7, C45B11.3/dhs-18, C46E10.7/
                                                srh-99, C54D10.3, D1054.10, D2045.6/cul-1, F07F6.1, F07F6.5/dct-5, F09B12.3, F17E5.1/lin-2, F28D1.5/
                                                thn-2, F29G9.1, F31C3.6, F36F2.1, F38E11.2/hsp-12.6, F38H4.8/ech-2, F41B5.4/cyp-33C3, F42G10.1,
                                                F43G9.5, F44D12.8, F47C10.2/btb-21, F52H3.5, F53C3.5, F56D5.5, F56G4.3/pes-2.2, F57C9.4, F57H12.7/
                                                mec-17, H04M03.1, H10D18.2/scl-12, K02B12.2, K02E11.5, K10B3.8/gpd-2, M01E11.2, M02D8.4, R03E9.1/
                                                mdl-1, R05F9.10/sgt-1, R12B2.5/mdt-15, R12H7.2/asp-4, T03F6.1/qdpr-1, T17H7.1, T20B5.3/oga-1,
                                                T21C9.8/ttr-23, T22G5.2/lbp-7, T24B8.5, W02D3.1, W03D2.6, W05H9.1, Y106G6H.7/sec-8, Y106G6H.9,
                                                Y38H6C.1/dct-16, Y43C5B.2, Y47D3B.7/sbp-1, ZK1127.10, ZK1290.6/rnh-1.1, ZK384.2/scl-20, ZK520.4/
                                                cul-2, ZK550.6, ZK637.8/unc-32, ZK829.6/tgt-1
Sulfate assimilation                    0.00001 B0218.3/pmk-1, B0412.2/daf-7, B0478.1/jnk-1, C47G2.2/unc-130, C53D6.2/unc-129, F38A6.1/pha-4,
                                                F43C1.2/mpk-1, T23H2.5/rab-10, Y11D7A.4/rab-28
Pyrimidine metabolism                   0.00113 B0304.1/hlh-1, B0478.1/jnk-1, B0547.1/csn-5, C04E7.2/sor-3, C07B5.5/nuc-1, C25D7.3/sdc-3, C34E10.7/
                                                cnd-1, C37A2.4/cye-1, C47G2.2/unc-130, F14F3.1/vab-3, F38A6.1/pha-4, F56A8.7/unc-64, K01G5.2/hpl-
                                                2, Y47D3A.6/tra-1, ZK520.4/cul-2
Pyridoxal phosphate salvage             0.00176 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1, Y18D10A.5/gsk-3, Y38F1A.10/max-2
pathway
Oxytocin receptor mediated              0.00236 B0478.1/jnk-1, B0547.1/csn-5, C44H4.6, F43C1.2/mpk-1, Y11D7A.4/rab-28, Y18D10A.5/gsk-3
signaling
Interferon-gamma signaling              0.00251 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1
Glycosphingolipid biosynthesis -        0.00297 T14F9.3/hex-1, T26C5.3
ganglio series
Cyanoamino acid metabolism              0.00340 B0035.8 48, B0304.1/hlh-1, B0478.1/jnk-1, B0547.1/csn-5, C02B8.4/hlh-8, C04E7.2/sor-3, C07B5.5/
                                                nuc-1, C09G9.7, C18A3.1, C25A1.11/aha-1, C25D7.3/sdc-3, C29F9.5, C34E10.7/cnd-1, C37A2.4/cye-1,
                                                C47G2.2/unc-130, F11A10.1/lex-1, F14F3.1/vab-3, F22D3.1/ceh-38, F22F1.1/hil-3, F38A6.1/pha-4,
                                                F45F2.4 7, F54C8.2/cpar-1, F56A8.7/unc-64, K01G5.2/hpl-2, K02B9.4/elt-3, R03E9.1/mdl-1, R05F9.10/
                                                sgt-1, R07B1.1/vab-15, R13H8.1/daf-16, T05A6.1/cki-1, T19B10.11/mxl-1, T27F2.1/skp-1, W06E11.1,
                                                Y39B6A.2/pph-5, Y47D3A.6/tra-1, Y47D3B.7/sbp-1, Y49E10.1/rpt-6, Y57E12AL.5/mdt-6, ZC204.2,
                                                ZK131.7 13, ZK520.4/cul-2, ZK652.5/ceh-23
Taurine/hypotaurine metabolism          0.00348 F56A8.7/unc-64, K02D10.5, T10H9.3, Y22F5A.3/ric-4
Glycolysis/Gluconeogenesis              0.00365 AC3.7/ugt-1, C05C8.3/fkb-3, C06B3.4/stdh-1, C07B5.5/nuc-1, F11A5.12/stdh-2, F38E11.2/hsp-12.6,
                                                K10B3.8/gpd-2, R03E9.1/mdl-1, R12B2.5/mdt-15, R13H8.1/daf-16, T22G5.2/lbp-7, T28B8.2/ins-18
Selenocompound metabolism               0.00365 AC3.7/ugt-1, C05C8.3/fkb-3, C06B3.4/stdh-1, C07B5.5/nuc-1, F11A5.12/stdh-2, F38E11.2/hsp-12.6,
                                                K10B3.8/gpd-2, R03E9.1/mdl-1, R12B2.5/mdt-15, R13H8.1/daf-16, T22G5.2/lbp-7, T28B8.2/ins-18
Insulin_IGF pathway-protein kinase B 0.00404 C44H4.6, C47G2.2/unc-130, F38A6.1/pha-4, Y18D10A.5/gsk-3
signaling cascade
Salvage pyrimidine ribonucleotides      0.00417 F42G9.7/snt-2, K02D10.5, Y22F5A.3/ric-4
Tetrahydrofolate biosynthesis           0.00417 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1
Apoptosis signaling                     0.00503 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1, Y18D10A.5/gsk-3, Y38F1A.10/max-2
Glycosaminoglycan degradation           0.00520 K09E4.4, T14F9.3/hex-1
 Lejeune et al. BMC Genomics 2012, 13:91                                                                                                    Page 9 14
http://www.biomedcentral.com/1471-2164/13/91




Table 2 Pathway analysis 399 genes reduced 128Q-neuron dysfunction knocked RNAi
(Continued)
Angiogenesis                            0.00520 C06B3.4/stdh-1, F11A5.12/stdh-2, K04A8.5
mRNA splicing                           0.00534 F56A8.7/unc-64, K02D10.5, Y22F5A.3/ric-4, Y48B6A.8/ace-3
Muscarinic acetylcholine receptor 1     0.00608 F56A8.7/unc-64, K02D10.5, Y22F5A.3/ric-4, Y48B6A.8/ace-3 3 signaling
Alanine biosynthesis                    0.00769 K02D10.5, K08F8.4/pah-1, Y22F5A.3/ric-4
Butanoate metabolism                    0.00777 C06B3.4/stdh-1, F11A5.12/stdh-2, K03A1.5/sur-5, T02G5.7
5-Hydroxytryptamine biosynthesis        0.00798 K02D10.5, Y22F5A.3/ric-4
Interleukin signaling                   0.00974 C47G2.2/unc-130, F38A6.1/pha-4, F43C1.2/mpk-1, Y18D10A.5/gsk-3
Amino sugar nucleotide sugar        0.01084 C01F1.3, C53B4.7/bre-1, K08E3.5, T14F9.3/hex-1
metabolism
Metabotropic glutamate receptor         0.01254 F56A8.7/unc-64, K02D10.5, Y22F5A.3/ric-4
group II pathway
Linoleic acid metabolism                0.01511 C06B3.4/stdh-1, F11A5.12/stdh-2
Beta3 adrenergic receptor signaling     0.01511 K02D10.5, Y22F5A.3/ric-4
Integrin signaling                      0.01742 B0218.3/pmk-1, B0478.1/jnk-1, C27B7.8/rap-1, C36B1.1/cle-1, F43C1.2/mpk-1
p53 pathway glucose deprivation      0.01908 C47G2.2/unc-130, F38A6.1/pha-4, F48E8.1/lon-1, Y18D10A.5/gsk-3
5-Hydroxytryptamine degredation         0.01939 K02D10.5, Y22F5A.3/ric-4
Ornithine degradation                   0.02121 B0218.3/pmk-1, B0478.1/jnk-1, T19B10.11/mxl-1
Cortocotropin releasing factor          0.02412 K02D10.5, Y22F5A.3/ric-4
receptor signaling
FGF signaling                           0.02627 B0218.3/pmk-1, B0478.1/jnk-1, F26E4.1/sur-6, F43C1.2/mpk-1
N-acetylglucosamine metabolism          0.02712 F56A8.7/unc-64, K02D10.5, T02C12.1/hum-5, Y22F5A.3/ric-4, Y48B6A.8/ace-3
5HT3 type receptor mediated             0.02928 K02D10.5, Y22F5A.3/ric-4
signaling
B cell activation                       0.02939 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1
Fructose mannose metabolism         0.03565 C06B3.4/stdh-1, C53B4.7/bre-1, F11A5.12/stdh-2
Pantothenate CoA biosynthesis       0.04074 F25H9.6, T04G9.4
Alzheimer disease-amyloid secretase     0.04074 K02D10.5, Y22F5A.3/ric-4
pathway
Beta1 adrenergic receptor signaling     0.04074 K02D10.5, Y22F5A.3/ric-4
Beta2 adrenergic receptor signaling     0.04074 K02D10.5, Y22F5A.3/ric-4
EGF receptor signaling                  0.04229 B0218.3/pmk-1, B0478.1/jnk-1, C27B7.8/rap-1, F43C1.2/mpk-1
Toll receptor signaling                 0.04494 C08B6.9/aos-1, F11A10.1/lex-1, F40G9.3/ubc-20, Y49E10.1/rpt-6
Alanine, aspartate glutamate        0.04494 C04E7.2/sor-3, C34E10.7/cnd-1, C47G2.2/unc-130, F57H12.7/mec-17
metabolism
Serine glycine biosynthesis             0.04620 B0478.1/jnk-1, F43C1.2/mpk-1, Y38F1A.10/max-2
Lysine biosynthesis                     0.04869 C25A11.4/ajm-1, C36B1.1/cle-1, F17E5.1/lin-2, F22B5.1/evl-20, F43C9.4/mig-13, F56A8.7/unc-64,
                                                Y22F5A.3/ric-4
Pathway analysis based hypergeomeric tests using pathways Wormbook, KEGG Panther. P < 0.05 considered significant results shown increasing P values.


(S score) available (genes modulate                           Additional file 10: Table S9). Modules variable sizes
128Q-neuron dysfunction produce effect                             obtained (2-50 genes) suppression knocked RNAi). modules resulting                             aggravation 128Q-neuron dysfunction. note, small analysis annotated using Gene Ontology,                          modules equally significant compared large mod-
KEGG Panther pathways gene lists                          ules size resulting modules dri-
(conserved genes, druggable genes, htt partners, genes                        ven stable best balance gene
involved autophagy, mitochondrial function                             connectivity gene activity spectral
synaptic activity). analyses identified reli-                    decomposition process  Materials Methods).
able set 286 modifier genes distributed 137                          modules content visualized using modules suppression 128Q-neuron dysfunction                         freely-accessible database  http://www.broca.inserm.
RNAi 105 modules aggravation 128Q-neuron                           fr/EHDN2/RNAiscreen) contains query page dysfunction RNAi (Additional file 9: Table S8;                             interactive graphical interface [36]. network-based
 Lejeune et al. BMC Genomics 2012, 13:91                                                                     Page 10 14
http://www.biomedcentral.com/1471-2164/13/91




approach confirmed trends observed gene set            intersection C. elegans RNAi data
enrichment analysis, detection pathways         gene dysregulation data HD mice (Figure 4). involved metabolism, immune response develop-          49 genes including Acy1, Sh3gl3, Snw1, Aars,
ment. Additionally, provided insights possible    Ppp5 Gpi1 oppositely dysregulated mechanisms RNAi hits potentially interact           CHL2 mice compared R6/2 mice (Figure 4), illustrat-
modify 128Q-neuron dysfunction. notably detected           ing differences exist modules seeded RNAi hits annotated           models molecular level. contrast, genes ‘Huntington’s disease’, ‘Parkinson’s disease’ ‘pantho-    involved variety biological processes tenate kinase activity’, previously associated     modulate 128Q-neuron dysfunction knocked- neurodegeneration [45]. largely, detected        RNAi dysregulated CHL2 modules annotated biological processes established        R6/2 mice (Figure 4), illustrating data comparison strongly suspected  [3] review HD mechan-       using substractive analysis useful target
isms) role neurodegenerative disease patho-      prioritisation. Notably, 12 genes suppress 128Q-
genesis ‘oxidative phosphorylation’, ‘cholesterol     neuron dysfunction knocked RNAi C.
biosynthesis’ ‘cell cycle’. Interestingly, mod-   elegans observed regulated ules annotated cell differentiation survival     CHL2 R6/2 mice, suggesting inhibiting pathways ‘Wnt signaling’, pathway suspected         genes elicit neuroprotection HD.  role HD pathogenesis [46], ‘apoptosis sig-       phenylalanine-4-hydroxylase Pah, appeared naling’ ‘integrin signaling’, suggesting        particularly interesting druggable gene pathways targeted therapeutic intervention       acts upstream tyrosine-dopamine biosynthesis HD. Annotations metabolic pathways             increased dopamine levels previously asso-
‘sucrose metabolism’, ‘pentose phosphate pathway’         ciated early HD phenotypes hyperkinesia
‘cholesterol biosynthesis’ detected, consistent     [49]. notion metabolic pathways tar-
geted therapeutic intervention HD [3,47]. Addi-        Discussion
tionally, modules annotated genes         aim study collect information HD druggable genes  notably            genes pathways act modifiers observed modules suppression 128Q-neu-          early stage mutant htt toxicity HD neuron
ron dysfunction RNAi; Additional file 9: Table         dysfunction. end, used vivo model S8), htt partners, genes involved autophagy, mito-     screen gene inactivations modulate neuronal
chondrial function synaptic activity,       dysfunction induced expanded-polyQ expression illustrated relevance dataset neuroprotec-      C. elegans, used network-boosted analysis tive target discovery HD.                                  enhance identification candidate pathways                                                               evaluated mammalian systems. Modifiers 128Q-neuron dysfunction C. elegans        identified 662 hits evaluation 6034 genes.
dysregulated striatum CHL2 knock mice     Compared RNAi screens based biochemical pro- R6/2 transgenic mice                                       cesses protein aggregation [38-40], relatively assess relevance RNAi data       high number hits study likely reflect didate target profiling discovery HD,          multigenic nature behavioral phenotypes compared dataset striatal gene expression data         response touch changes polyQ-
collected mouse models HD. Given 128Q            expanded htt expression levels. Previously-identified
nematodes recapitulate progressive neuron dysfunction,        modulators neuron dysfunction expanded-polyQ occur HD cell loss, compared           nematodes change transgene expression levels RNAi data striatal gene expression data collected      [14,18], suggesting RNAi effects CHL2(Q150/Q150) knock mice, model               changes htt expression levels. recapitulate progressive neuronal injury similar       contrast 128Q-neuron dysfunction, neuronal early course HD [48]. reach      dysfunction produced normal polyQ expression specific level comparison, compared           trangenic nematodes directly relevant HD data striatal gene expression data collected      pathogenesis. Microarray analysis gene expression R6/2 transgenic mice, model exhibits rapid         touch receptor cells isolated fluorescence-activated
phenotypic changes induced short N-terminal           cell sorting indicated 18 2000
fragment mutant htt [10]. 662 modifiers          genes dysregulated 128Q expression dysregu- 128Q-neuron dysfunction C. elegans, 239 genes           lated 19Q expression (submitted ,  conserved mouse. genes            eral expanded-polyQ cytotoxicity  Lejeune et al. BMC Genomics 2012, 13:91                                                                                        Page 11 14
http://www.biomedcentral.com/1471-2164/13/91




 Figure 4 Overlap 239 conserved modifiers 128Q-neuron dysfunction C-elegans genes dysregulated striatum
 CHL2 knock mice R6/2 transgenic mice.   Overlap dysregulated genes mouse striatum suppressors  128Q-neuron dysfunction mouse orthologs. Numbers genes indicated. lists genes intersection nematode
 mouse datasets indicated graphs. (B) Overlap dysregulated genes mouse striatum enhancers 128Q-
 neuron dysfunction mouse orthologs. numbers genes indicated. lists genes intersection nematode  mouse datasets indicated graphs. genes oppositely dysregulated CHL2 mice compared R6/2 mice (yellow
 tags). panels, red circles indicate C. elegans genes modify 128Q-neuron toxicity. *Druggable genes.


previously identified showed effect normal polyQ                  screening perspective. example illustrated
cytotoxicity [14,18]. Additionally, observed                    N-acetylgalactosaminyltransferases (gly-9 greater 90  modifiers 128Q-neuron dys-                   gly-3), family enzymes involved neuron differen-
function showed effect 19Q nematodes using                      tiation survival [50].
subset 243 genes identified RNAi screening                        major feature network-boosted analysis 128Q nematodes. Collectively, observations sug-                   reduce data complexicity highlighting individual
gest mechanisms neuron dysfunction 19Q                   pathways possibly inter-connected pathways nematodes [14] different underlying                  embedded modules seeded gene activity.
strong level neuron dysfunction 128Q nematodes.                   respect, network-boosted data analysis specific modifiers expanded-polyQ cytotoxicity                 RNAi dataset instructive compared sole constitute preferred HD targets,                       use annotations gene set enrichment analysis.
exclude possibility non-specific modifiers                  role variety pathways suggested neuron dysfunction polyQ nematodes belong                     gene set enrichment analysis, network-boosted analysis core machinery neuron differentiation survi-                emphasized role pathways val, potential                   comprehensive fashion, providing new insights  Lejeune et al. BMC Genomics 2012, 13:91                                                                                     Page 12 14
http://www.biomedcentral.com/1471-2164/13/91



 genes associated pathways interact            chaperone [51], aggravates neuron dysfunction modules. Furthermore, network-boosted analysis          knocked RNAi regulated identified pathways detected gene set enrichment        CHL2 mice, (ii) sel-8, C. elegans gene encodes analysis. indicated pathways embedded         nuclear protein required lin-12/NOTCH signaling,
modules resulting network-boosted analysis            neuron survival activities [52], line database http://www.broca.inserm.fr/            aggravates 128Q-neuron dysfunction knocked-
EHDN2/RNAiscreen), role neurodegenerative dis-           RNAi, (iii) jnk-1/JNK, gene promote HD
ease pathways neurodevelopmental/cell survival             pathology rat model disease [53] sup-
pathways modulation expanded-polyQ cyto-             presses 128Q-neuron dysfunction knocked toxicity emphasized, provide guidance         RNAi, (iv) pnk-1/PanK4, gene encodes selection candidate targets neuroprotection      panthotenate kinase suppresses 128Q-neuron dys-
HD. annotation modules resulting net-          function knocked RNAi, consis-
work-boosted analysis identified clusters enriched          tent pathological role panthotenate kinases
genes druggable genes, htt partners        neurodegeneration [45]. Additionally, comparison genes involved autophagy, mitochondrial function        data gene dysregulation striatum synaptic activity  gene classes quer-     CHL2 knock mice versus R6/2 transgenic
ied using line database), providing additional gui-     mice indicated dataset contains infor-
dance neuroprotective target discovery HD.          mation relevant HD target selection illustrated important note hypothesis underlying         proposed inhibition phenylalanine-4-hydroxylase
network-based approaches highly-interconnected         candidate strategy reduce early HD phenotypes
genes similar biological activities.        associated transient excess dopamine
respect, network-boosted analysis data pre-      [49].
dictive genes decrease increase
128Q-neuron dysfunction knocked                   Conclusions
RNAi, showed effect borderline          conclusion, results provide new insights effects RNAi screen. increase        genes pathways regulate dysfunction
number candidate targets considered neuro-        death neurons expressing mutant polyQs,
protective intervention, decreases risk noise       emphasizing role specific metabolic, developmental
associated RNAi screens favors inclusion          pro-survival pathways. models HD potentially-interesting information multi-model         used screen modifiers mutant polyQ
target discovery.                                              toxicity genes dysregulated mutant htt.    Multi-model target discovery strongly expected        context, use cross-species data integration enhance drug discovery process neuroprotection         analysis RNAi dataset datasets HD. standard method validation modi-           anticipated boost prediction prioritisation fiers neuronal dysfunction instructed simple          neuroprotective targets HD, investi-
models HD pathogenesis relies target validation       gated additional studies. mouse. feasible test mouse genes supported modifiers neuronal             Additional material
decline simple models, outcome functional
screen screens analyzed using data            Additional file 1: Figure S1. Distribution S scores primary
integration procedures selection best       screen 128Q;rrf-3 nematodes. graph shows S scores 4017
                                                                RNAi clones did elicit lethality developmental abnormalities.
targets validation rely target expression levels    S score calculated [(Percent response - mean baseline)/mean activity multiple models HD.               baseline]. maximally-achievable score 4.55 (100  response objectives data integration assess relevance       touch) smallest score -1 (complete loss touch response).
                                                                blue line indicate mean baseline (S = 0). Dooted blue lines simple-model data mouse models, lar-             mean baseline ± SD*2.6. Clones S scores falling outside gely human neurodegenerative disease.                mean baseline ± SD*2.6 interval retained secondary screen.
respect, notable modifiers 128Q-neu-      Additional file 2: Table S1. List 2211 genes caused lethality
ron dysfunction screen previously             developmental abnormalities knocked RNAi.
associated pathogenesis neurodegenerative           Additional file 3: Table S2. List 3823 genes showed
                                                                effect modified 128Q-neuron dysfunction knocked diseases HD AD, suggesting C. ele-          RNAi primary screen.
gans dataset relevant HD pathogenesis higher           Additional file 4: Table S3. List 662 genes modified 128Q-
order models disease. example            neuron dysfunction knocked RNAi secondary
case genes retained network-boosted analysis        screen.
including   dnj-1/DNAJ, gene encodes DNAJ
 Lejeune et al. BMC Genomics 2012, 13:91                                                                                                           Page 13 14
http://www.biomedcentral.com/1471-2164/13/91




                                                                                        Neuropathologic genetic evidence role Huntington’s
    Additional file 5: Table S4. List 15 genes modified 19Q-                disease pathogenesis. Proc Natl Acad Sci USA 2001, 98(4):1811-1816.
    neuron dysfunction knocked RNAi.                                 6.    Goehler H, Lalowski M, Stelzl U, Waelter S, Stroedicke M, Worm U,
    Additional file 6: Table S5. List 15 genes modified 128Q-               Droege  Lindenberg KS, Knoblich M, Haenig C, et al: protein
    neuron dysfunction secondary screen previously                      interaction network links GIT1, enhancer huntingtin aggregation,
    reported modify polyQ aggregation knocked RNAi.                     Huntington’s disease. Mol Cell 2004, 15(6):853-865.
    Additional file 7: Table S6. Gene Ontology classification genes       7.    Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar 
    suppressed 128Q-neuron dysfunction knocked RNAi.                       Strand  Torcassi C, Savage J, Hurlburt  et al: Huntingtin interacting
                                                                                        proteins genetic modifiers neurodegeneration. PLoS Genet 2007,
    Additional file 8: Table S7. Gene Ontology classification genes             3(5):e82.
    aggravated 128Q-neuron dysfunction knocked RNAi.                 8.    Holbert S, Dedeoglu  Humbert S, Saudou F, Ferrante RJ, Neri C: Cdc42-
    Additional file 9: Table S8. Modules (n = 137) generated network-                interacting protein 4 binds huntingtin: neuropathologic     boosted analysis suppression 128Q-neuron dysfunction RNAi.                biological evidence role Huntington’s disease. Proc Natl Acad Sci
    Additional file 10: Table S9. Modules (n = 105) generated network-               USA 2003, 100(5):2712-2717.
    boosted analysis aggravation 128Q-neuron dysfunction RNAi.          9.    Hodges  Strand AD, Aragaki AK, Kuhn  Sengstag T, Hughes G,
                                                                                        Elliston LA, Hartog C, Goldstein DR, Thu D, et al: Regional cellular
                                                                                        gene expression changes human Huntington’s disease brain. Hum Mol
                                                                                        Genet 2006, 15(6):965-977.
                                                                                  10.   Kuhn  Goldstein DR, Hodges  Strand AD, Sengstag T, Kooperberg C,
Acknowledgements                                                                        Becanovic K, Pouladi MA, Sathasivam K, Cha JH, et al: Mutant huntingtin’s grateful Cheryl Wellington Michael Hayden (University                  effects striatal gene expression mice recapitulate changes
British Columbia, Canada) providing constructs encoding htt 128                observed human Huntington’s disease brain differ Glns Jean Philippe Vert help bioinformatics. thank Hazare               mutant huntingtin length wild-type huntingtin dosage. Hum Mol
Nouari, David Bragado, Salima Abderrahmane, Sabine Cleofax, Sidonie                 Genet 2007, 16(15):1845-1861.
Vivequin technical assistance, Jim Wang George Yohrling (CHDI         11.   Smith R, Brundin P, Li JY: Synaptic dysfunction Huntington’s disease: Foundation) lists genes involved autophagy, mitochondrial activity,           new perspective. Cell Mol Life Sci 2005, 62(17):1901-1912. synaptic activity. J P. supported Young Researcher Award           12.   Chalfie M: Neurosensory mechanotransduction. Nat Rev Mol Cell Biol 2009, Inserm. R.V. supported Poste Vert fellowship Inserm.             10(1):44-52.
work supported Inserm, Agence Nationale la Recherche                13.   Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C:
(ANR), Fondation pour la Recherche Médicale (FRM), Paris, France,               Expanded polyglutamines Caenorhabditis elegans cause axonal
Hereditary Disease Foundation (USA) European Huntington Disease                 abnormalities severe dysfunction PLM mechanosensory neurons
Network (Euro-HD, Germany).                                                             cell death. Proc Natl Acad Sci USA 2001, 98(23):13318-13323.
                                                                                  14.   Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H,
Author details                                                                          Neri C: Resveratrol rescues mutant polyglutamine cytotoxicity 1
 INSERM, Unit 894, Laboratory Neuronal Cell Biology Pathology,                   nematode mammalian neurons. Nat Genet 2005, 37(4):349-350.
75014 Paris, France. 2University Paris Descartes, EA 4059, 75014 Paris,        15.   Du H, Chalfie M: Genes regulating touch cell development France. 3Université Montreal, CRCHUM Centre d’excellence                          Caenorhabditis elegans. Genetics 2001, 158(1):197-207.
neuromique, Hôpital Notre-Dame, Montreal, QC,H2W 1T8 Canada. 4Mines               16.   Brenner S: genetics Caenorhabditis elegans. Genetics 1974,
ParisTech, CBIO, Fontainebleau, 75006 Paris, France. 5Curie Institute, Research         77(1):71-94.
Center, 75005 Paris, France. 6INSERM, Unit 900, Paris, 75005 France. 7Buck        17.   Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C:
Institute, Novato, CA 94945, USA.                                                       Expanded polyglutamines Caenorhabditis elegans cause axonal
                                                                                        abnormalities severe dysfunction PLM mechanosensory neurons
Authors’ contributions                                                                  cell death. Proc Natl Acad Sci USA 2001, 98(23):13318-13323.
FXL, LM FP designed performed data analysis developed                 18.   Parker JA, Metzler M, Georgiou J, Mage M, Roder JC, Rose  Hayden MR,
database tools. CB contributed database developments. JPV contributed                Neri C: Huntingtin-interacting protein 1 influences worm mouse
essential tools data analysis. RVM, JAP CT designed performed C.            presynaptic function protects Caenorhabditis elegans neurons
elegans experiments. CN conceived supervised experiments. FXL CN                mutant polyglutamine toxicity. J Neurosci 2007,
wrote manuscript. authors read approved final manuscript.               27(41):11056-11064.
                                                                                  19.   Pavelec DM, Lachowiec J, Duchaine TF, Smith  Kennedy S: Requirement
Competing interests                                                                     ERI/DICER complex endogenous RNA interference sperm authors declare competing interests.                              development Caenorhabditis elegans. Genetics 2009, 183(4):1283-1295.
                                                                                  20.   Reboul J, Vaglio P, Rual JF, Lamesch P, Martinez M, Armstrong CM, Li S,
Received: 20 October 2011 Accepted: 13 March 2012                                       Jacotot L, Bertin N, Janky R, et al: C. elegans ORFeome version 1.1:
Published: 13 March 2012                                                                experimental verification genome annotation resource                                                                                         proteome-scale protein expression. Nat Genet 2003, 34(1):35-41.
References                                                                        21.   Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
1. Gil JM, Rego AC: Mechanisms neurodegeneration Huntington’s                     Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: tool     disease. Eur J Neurosci 2008, 27(11):2803-2820.                                     unification biology. Gene Ontology Consortium. Nat Genet 2000,
2. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J,                     25(1):25-29.
    Shehadeh J, Bertram L, Murphy  et al: Cleavage caspase-6 site     22.   Bauer S, Grossmann S, Vingron M, Robinson PN: Ontologizer 2.0     required neuronal dysfunction degeneration mutant                    multifunctional tool term enrichment analysis data
    huntingtin. Cell 2006, 125(6):1179-1191.                                            exploration. Bioinformatics 2008, 24(14):1650-1651.
3. Zuccato C, Valenza M, Cattaneo E: Molecular mechanisms potential           23.   Mootha VK, Lindgren CM, Eriksson KF, Subramanian  Sihag S, Lehar J,
    therapeutical targets Huntington’s disease. Physiol Rev 2010,                    Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al: PGC-1alpha-
    90(3):905-981.                                                                      responsive genes involved oxidative phosphorylation coordinately
4. Sun B, Fan W, Balciunas  Cooper JK, Bitan G, Steavenson S, Denis PE,               downregulated human diabetes. Nat Genet 2003, 34(3):267-273.
    Young Y, Adler B, Daugherty L, et al: Polyglutamine repeat length-            24.   Subramanian  Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
    dependent proteolysis huntingtin. Neurobiol Dis 2002, 11(1):111-122.             Paulovich  Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment
5. Holbert S, Denghien  Kiechle T, Rosenblatt  Wellington C, Hayden MR,             analysis: knowledge-based approach interpreting genome-wide
    Margolis RL, Ross CA, Dausset J, Ferrante RJ, et al: Gln-Ala repeat             expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550.
    transcriptional activator CA150 interacts huntingtin:
 Lejeune et al. BMC Genomics 2012, 13:91                                                                                                                  Page 14 14
http://www.biomedcentral.com/1471-2164/13/91




25. Kanehisa M, Goto S: KEGG: kyoto encyclopedia genes genomes.                     monooxygenase inhibition blood ameliorates neurodegeneration. Cell
    Nucleic Acids Res 2000, 28(1):27-30.                                                   2011, 145(6):863-874.
26. Lee  Lehner B, Crombie C, Wong W, Fraser AG, Marcotte EM: single             48.   Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB,
    gene network accurately predicts phenotypic effects gene                            Ren S, Li XJ, Albin RL, Detloff PJ: Neurological abnormalities knock     perturbation Caenorhabditis elegans. Nat Genet 2008, 40(2):181-188.                 mouse model Huntington’s disease. Hum Mol Genet 2001,
27. Li S, Armstrong CM, Bertin N, Ge H, Milstein S, Boxem M, Vidalain PO,                  10(2):137-144.
    Han JD, Chesneau  Hao T, et al: map interactome network            49.   Raymond LA, Andre VM, Cepeda C, Gladding CM, Milnerwood AJ,
    metazoan C. elegans. Science 2004, 303(5657):540-543.                              Levine MS: Pathophysiology Huntington’s disease: time-dependent
28. Chen N, Harris TW, Antoshechkin  Bastiani C, Bieri T, Blasiar D, Bradnam K,          alterations synaptic receptor function. Neuroscience 2011,
    Canaran P, Chan J, Chen CK, et al: WormBase: comprehensive data                      198:252-273.
    resource Caenorhabditis biology genomics. Nucleic Acids Res              50.   Yamashita T, Wu YP, Sandhoff R, Werth N, Mizukami H, Ellis JM, Dupree JL,
    2005, , 33 Database issue: D383-D389.                                                  Geyer R, Sandhoff K, Proia RL: Interruption ganglioside synthesis
29. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot  Li N, Berriz GF,         produces central nervous degeneration altered axon-glial
    Gibbons FD, Dreze M, Ayivi-Guedehoussou N, et al: proteome-                  interactions. Proc Natl Acad Sci USA 2005, 102(8):2725-2730.
    scale map human protein-protein interaction network. Nature               51.   Hageman J, van Waarde MA, Zylicz  Walerych D, Kampinga HH:     2005, 437(7062):1173-1178.                                                             diverse members mammalian HSP70 machine distinct
30. Giot L, Bader JS, Brouwer C, Chaudhuri  Kuang B, Li Y, Hao YL, Ooi CE,               chaperone-like activities. Biochem J 2011, 435(1):127-142.
    Godwin B, Vitols E, et al: protein interaction map Drosophila               52.   Ables JL, Breunig JJ, Eisch AJ, Rakic P: ch) just development: Notch
    melanogaster. Science 2003, 302(5651):1727-1736.                                       signalling adult brain. Nat Rev Neurosci 2011, 12(5):269-283.
31. Lee  Li  Marcotte EM: improved, bias-reduced probabilistic                53.   Perrin V, Dufour N, Raoul C, Hassig R, Brouillet E, Aebischer P, Luthi-Carter R,
    functional gene network baker’s yeast, Saccharomyces cerevisiae.                    Deglon N: Implication JNK pathway rat model     PLoS 2007, 2(10):e988.                                                             Huntington’s disease. Exp Neurol 2009, 215(1):191-200.
32. Rapaport F, Zinovyev  Dutreix M, Barillot E, Vert JP: Classification     microarray data using gene networks. BMC Bioinforma 2007, 8:35.                    doi:10.1186/1471-2164-13-91
33. Russ AP, Lampel S: druggable genome: update. Drug Discov Today              Cite article  Lejeune et al.: Large-scale functional RNAi screen     2005, 10(23-24):1607-1610.                                                         C. elegans identifies genes regulate dysfuncti